Advertisement
Advice from the leader of Cleveland Clinic Cancer Center
In spite of the challenges posed by the novel coronavirus pandemic, it is essential that patients with suspected, newly diagnosed or progressive cancers receive ongoing care.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Cleveland Clinic Cancer Center has continued to provide consultation and treatment during the pandemic, utilizing virtual visits and, when necessary, in-person clinical care with appropriate precautions.
In addition to serving patients in our own healthcare system, the cancer center has connected with oncologists in regions hard-hit by COVID-19 who have had to defer or delay cancer treatments, to offer temporary care until conditions improve and patients can resume seeing their own physicians. (Oncologists in need of this assistance should call Cleveland Clinic’s Cancer Answer Line, 866.223.8100.)
How is it possible to maintain patient services during this difficult time? The key is taking care of the cancer center’s workforce so they can care for others, says Cleveland Clinic Taussig Cancer Institute Chair Brian J. Bolwell, MD. That means addressing fears, sharing information regularly and transparently, and providing the support and encouragement people need to do their jobs.
Learn more about Dr. Bolwell’s approach to leading the cancer center and providing care during COVID-19 by reading his latest column in Oncology Times. In addition to heading Cleveland Clinic Cancer Center, Dr. Bolwell is Cleveland Clinic’s Director of Physician Leadership and Development.
Advertisement
Advertisement
Higher type 2 immunity observed in persistent CAR T cells
Pregnancy did not appear to increase the risk of recurrence in patients or complications in their children
Integrated program addresses growing need for comprehensive cancer care among adolescents, young adults and adults under 50 with early onset cancers
Studies find mTOR inhibitor may play key role in treating Hurthle cell carcinoma
Timing and type of side effects differ greatly from chemotherapy
Dedicated multidisciplinary teams support 84 ultra-rare cancers
New research from Cleveland Clinic helps explain why these tumors are so refractory to treatment, and suggests new therapeutic avenues
Combination of olaparib and carboplatin results in complete durable response for a patient with BRCA2 and “BRCAness” mutations